Fougera names SVP commercial operations
MELVILLE, N.Y. — Fougera Pharmaceuticals has promoted Walt Kaczmarek to serve as the company’s SVP commercial operations, the drug maker announced.
Kaczmarek, who joined the company in 2004, has been managing national accounts for Fougera’s three marketing divisions, including Fougera, PharmaDerm, and Savage Labs, for the past eight years. He recently began managing accounts for the managed care markets of Fougera’s branded division PharmaDerm, Fougera said.
”Walt has been an integral part of the steady growth of Fougera Pharmaceuticals,” said David Klaum, SVP, general manager at Fougera. “Walt has demonstrated his dedication to this company and its customers, and I am confident that he’ll continue to play a key role in our pursuit of increased business opportunities.”
More diagnoses to drive celiac disease market growth through decade
LONDON — The global market for celiac disease is expected to grow substantially over the decade as more people are diagnosed with the condition, according to a new report.
The report, by British market research firm GlobalData, found that the global celiac disease therapeutics market would be worth more than $512 million by 2017 and $664.4 million by 2019.
The firm noted that while people with celiac disease can treat it with a gluten-free diet, such diets are relatively expensive, limit nutritional variety and often restrict social activities, thus creating a significant unmet need for nondietary therapies.
The current drug pipeline is weak, the firm said, with no drugs in phase-3 clinical trials and only two in phase-2 trials that may not enter the market until later in the decade.
National Diabetes Prevention Program gets $10 million in funding from HHS
WASHINGTON — The Department of Health and Human Services is providing $10 million in fiscal year 2012 funding for the Centers for Disease Control and Prevention’s National Diabetes Prevention Program.
The NDPP is an initiative, authorized in 2010, which provides local communities with lifestyle change programs for preventing Type 2 diabetes. HHS’ decision was praised by several groups, including the American Diabetes Association and the Diabetes Advocacy Alliance.
“Expansion of the National Diabetes Prevention Program will allow more Americans with prediabetes to participate in a proven program to lower their risk for Type 2 diabetes and its dangerous complications,” American Diabetes Association board chairman L. Hunter Limbaugh said. “By putting this program in our communities, we are also making good on our investment into the groundbreaking National Institutes of Health research that showed we can prevent diabetes and we are helping to reduce long term healthcare costs.”
"We are very pleased by the $10 million that HHS approved for this highly successful approach to reducing the risk of diabetes," said Martha Rinker, chief advocacy officer of the American Association of Diabetes Educators, a Diabetes Advocacy Alliance member co-chair organization. "The DAA has been advocating for funds to bring this program to scale nationally. The funding will help bring this evidence-based lifestyle intervention to more people and more communities throughout the U.S. to help fight the diabetes epidemic."